Post-earnings recap
Reported
Wed, Nov 4, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Protagonist Therapeutics reported a better-than-expected EPS for the quarter, which contributed to a 5.15% increase in stock price. The lack of revenue data leaves some uncertainty, but the positive EPS surprise indicates potential operational improvements. Investors may view this as a step in the right direction for the company's future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | +65.40% |
| Revenue | N/A | N/A | N/A |
Management highlighted the positive EPS surprise as a sign of progress. They remain focused on advancing their clinical programs.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized ongoing efforts in their drug development pipeline.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—